International Biotechnology Trust’s Apellis Pharmaceuticals APLS Stock Holding History

International Biotechnology Trust’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-129,700	Closed	-$11.8M	–	66
2023 Q2	$11.8M	Buy	129,700 +98,000	+309%	+$8.46M	3.6%	8
2023 Q1	$2.09M	Hold	31,700	–	–	0.58%	38
2022 Q4	$1.64M	Buy	+31,700	New	+$1.68M	0.51%	38
2022 Q3	–	Sell	-1,470	Closed	-$32.5K	–	69
2022 Q2	$32.5K	Sell	1,470 -31,030	-95%	-$1.41M	0.34%	53
2022 Q1	$1.54M	Hold	32,500	–	–	0.35%	48
2021 Q4	$1.54M	Buy	+32,500	New	+$1.28M	0.34%	50
2021 Q3	–	Sell	-23,400	Closed	-$1.48M	–	70
2021 Q2	$1.48M	Hold	23,400	–	–	0.39%	45
2021 Q1	$1M	Buy	+23,400	New	+$1.11M	0.26%	47

Other funds holding APLS

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

International Biotechnology Trust's APLS Position: Q3 2023 in Review

International Biotechnology Trust sold out of Apellis Pharmaceuticals (APLS) in Q3 2023, closing a stake of 129,700 shares — an estimated $11.8M sold.

International Biotechnology Trust first reported a position in APLS in Q1 2021 and held it in 8 quarters. The position peaked at $11.8M in Q2 2023. 256 funds tracked by Wall St. Rank hold APLS as of Q3 2023.

International Biotechnology Trust reported no remaining Apellis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
International Biotechnology Trust sold 129,700 Apellis Pharmaceuticals shares in Q3 2023, an estimated $11.8M.
International Biotechnology Trust first reported a position in Apellis Pharmaceuticals in Q1 2021 and held it in 8 quarters.
International Biotechnology Trust's Apellis Pharmaceuticals position peaked at $11.8M in Q2 2023.
256 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.